Urgency to Expand SGLT2i Use in HF Heightened by More DELIVER Data

(MedPage Today) -- NATIONAL HARBOR, Md.--The benefits of dapagliflozin (Farxiga) persisted in various secondary analyses of the DELIVER trial, building confidence for real-world benefits from the SGLT2 inhibitor for heart failure (HF) patients...